圣诺医药(02257.HK)曾涨38% 治疗原位鳞状细胞癌疗法获美国FDA具体指导建议

阿斯达克财经04-17

圣诺医药－Ｂ(02257.HK) 今日(17日)高开14.95%报6.92元，早段曾涨37.9%高见8.3元。现报7.38元，升22.59%，成交436.66万股，涉资3,315.2万元。公司公布，已获得美国食品药监局(FDA)关于其用于进一步研发治疗原位鳞状细胞癌(isSCC)的新型siRNA疗法STP705所要求的C类会议的书面答复。FDA已为非临床及临床研究、对拟议的II/III期及III期...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2428355334?lang=zh_CN&edition=full","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20220513155537706_s.jpg","is_english":false,"pubTime":"2024-04-17 09:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2428355334","market":"hk","top_or_hot":-1,"title":"圣诺医药(02257.HK)曾涨38% 治疗原位鳞状细胞癌疗法获美国FDA具体指导建议","media":"阿斯达克财经","content":"<div>\n<p>圣诺医药－Ｂ(02257.HK) 今日(17日)高开14.95%报6.92元，早段曾涨37.9%高见8.3元。现报7.38元，升22.59%，成交436.66万股，涉资3,315.2万元。公司公布，已获得美国食品药监局(FDA)关于其用于进一步研发治疗原位鳞状细胞癌(isSCC)的新型siRNA疗法STP705所要求的C类会议的书面答复。FDA已为非临床及临床研究、对拟议的II/III期及III期...</p>\n\n<a href=\"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1342846/latest-news/AAFN\">网页链接</a>\n\n</div>\n","source":"aastocks_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>圣诺医药(02257.HK)曾涨38% 治疗原位鳞状细胞癌疗法获美国FDA具体指导建议</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n圣诺医药(02257.HK)曾涨38% 治疗原位鳞状细胞癌疗法获美国FDA具体指导建议\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-04-17 09:47 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1342846/latest-news/AAFN><strong>阿斯达克财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>圣诺医药－Ｂ(02257.HK) 今日(17日)高开14.95%报6.92元，早段曾涨37.9%高见8.3元。现报7.38元，升22.59%，成交436.66万股，涉资3,315.2万元。公司公布，已获得美国食品药监局(FDA)关于其用于进一步研发治疗原位鳞状细胞癌(isSCC)的新型siRNA疗法STP705所要求的C类会议的书面答复。FDA已为非临床及临床研究、对拟议的II/III期及III期...</p>\n\n<a href=\"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1342846/latest-news/AAFN\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1342846/latest-news/AAFN","article_id":"2428355334","we_media_id":null,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20220513155537706_s.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2428355334","pubTimestamp":1713318420,"sourceInfo":{"source_id":"aastocks_highlight","name":"阿思達克財經"},"weMediaInfo":null,"summary":"圣诺医药－Ｂ今日高开14.95%报6.92元，早段曾涨37.9%高见8.3元。现报7.38元，升22.59%，成交436.66万股，涉资3,315.2万元。公司公布，已获得美国食品药监局关于其用于进一步研发治疗原位鳞状细胞癌的新型siRNA疗法STP705所要求的C类会议的书面答复。FDA已为非临床及临床研究、对拟议的II/III期及III期临床研究的修订，以及在候选药物STP705中使用两种活性成分所需的进一步论证提供明确的具体指导建议。目前，公司已根据FDA的指导建议启动所需的临床前研究。沽空资料截至 2024-04-16 16:25。","collect":0,"end_time":0,"defaultTopTitle":"aastocks.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1161":"生物科技","02257":"圣诺医药-B"},"translate_title":"Sinopharm (02257. HK) once rose 38% to treat squamous cell carcinoma in situ and received specific guidance from the US FDA","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02257":1},"content_text":"圣诺医药－Ｂ(02257.HK) 今日(17日)高开14.95%报6.92元，早段曾涨37.9%高见8.3元。现报7.38元，升22.59%，成交436.66万股，涉资3,315.2万元。公司公布，已获得美国食品药监局(FDA)关于其用于进一步研发治疗原位鳞状细胞癌(isSCC)的新型siRNA疗法STP705所要求的C类会议的书面答复。FDA已为非临床及临床研究、对拟议的II/III期及III期临床研究的修订，以及在候选药物STP705中使用两种活性成分所需的进一步论证提供明确的具体指导建议。目前，公司已根据FDA的指导建议启动所需的临床前研究。(jl/w)(港股报价延迟最少十五分钟。沽空资料截至 2024-04-16 16:25。)AASTOCKS新闻","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2428355334"}